Abi-Saab Walid 4

What Happened
Abi‑Saab Walid, Chief Medical Officer of uniQure (QURE), exercised/converted derivative awards and sold shares on May 8, 2026. The filing reports: exercised 25,000 shares at $5.59 (cash cost $139,750) and a conversion/exercise of 25,000 shares shown at $0.00 (derivative). On the same day he sold 25,000 shares at a weighted average price of $25.10 (proceeds ~$627,500) and 20,000 shares at $25.00 (proceeds $500,000), for total sale proceeds of approximately $1,127,500. These transactions were effected under a Rule 10b5‑1 plan.

Key Details

• Transaction date: May 8, 2026. Form 4 filed May 12, 2026 (timely within the two‑business‑day SEC window).
• Exercises/conversions: 25,000 shares acquired at $5.59 (cost $139,750); 25,000 shares listed as exercised/converted at $0.00 (derivative).
• Sales: 45,000 shares sold (25,000 at $25.10 weighted avg; 20,000 at $25.00). Price range for sales: $25.00–$25.29 (filing footnote). Total reported sale proceeds ≈ $1,127,500.
• Shares owned after transaction: not disclosed in the provided filing.
• Notable footnotes: transactions were made pursuant to a 10b5‑1 trading plan adopted Sept 26, 2025 (Footnote F1); sale price shown as a weighted average with range provided and further breakdown available on request (F2); the option referenced was granted Mar 1, 2024 with standard vesting schedule (F3).

Context: The pattern here is an exercise/ conversion of derivatives followed by same‑day open‑market sales — effectively realizing gains rather than an outright purchase (not a bullish purchase signal). The 10b5‑1 plan means the sales were pre‑arranged; filings are factual and do not indicate the insider’s motive.